The Middle East viral vectors and plasmid DNA manufacturing market is valued at USD 270 billion in 2025 and is projected to reach USD 957.9 billion by 2035, growing at a CAGR of 13.50%, driven by rising gene therapy demand and biopharma investments.

Middle East Viral Vectors and Plasmid DNA Manufacturing Market Statical Scope

The viral vector and plasmid DNA manufacturing sector in the Middle East is gaining traction due to the rising government funding aimed at enhancing local biomanufacturing capabilities, thereby reducing reliance on external sources for vaccines and other biologics . This focus has intensified efforts to promote AAV, lentivirus, adenovirus, and other vectors relevant to gene therapies and DNA-based vaccines. The region is continually advancing its infrastructure, which is increasingly attracting attention to healthcare and enabling the conduct of clinical research activities.

Middle East Viral Vectors and Plasmid DNA Manufacturing Market Share, By Vector Type, 2025 (%)

• Adeno-associated virus (AAV)- Adeno-associated virus (AAV) leads the market, with a share of 25%, driven by strong delivery efficiency and favorable safety characteristics.
• Lentivirus- Lentivirus holds a significant share of 21%, supported by rising use in cell therapy development and stable gene transfer applications.
• Adenovirus- Adenovirus represents a segment, with a share of 15%, supported by its applications in vaccine development and targeted gene delivery.
• Plasmids- Plasmids account for a notable share of 19%, driven by demand for DNA-based therapeutics and support for vector production processes.

Middle East Viral Vectors and Plasmid DNA Manufacturing Market Share, By Workflow, 2025 (%)

• Upstream manufacturing- Upstream manufacturing dominates the market, with a share of 60%, driven by increasing demand for vector production and rising cell culture activities.
• Downstream manufacturing- Downstream manufacturing a share of 40%, supported by growing requirements for purification, processing, and quality assurance.

Middle East Viral Vectors and Plasmid DNA Manufacturing Market Share, By Application, 2025 (%)

• Gene therapy- Gene therapy leads the market, with a share of 40%, driven by increasing focus on advanced therapeutic development and rising clinical activity in gene-based treatments.
• Cell therapy- Cell therapy holds a significant share of 25%, supported by growing investment in advanced therapies and growing development pipelines.
• Research applications- Research applications account for a notable share of 15%, driven by ongoing innovation and preclinical research programs.
• Antisense & RNAi therapy- Antisense & RNAi therapy hold a share of 12%, supported by increasing interest in next-generation nucleic acid therapeutics.

Middle East Viral Vectors and Plasmid DNA Manufacturing Market Share, By End-use, 2025 (%)

• Pharmaceutical and biopharmaceutical companies- Pharmaceutical and biopharmaceutical companies dominate the market, with 70% share, driven by strong outsourcing demand and large-scale production requirements.
• Research institutes- Research institutes hold a significant share of 30%, supported by continued research activity and development of novel vector technologies.

Middle East Viral Vectors and Plasmid DNA Manufacturing Market Share, By Disease, 2025 (%)

• Cancer- Cancer leads the market, with a share of 50%, driven by a strong focus on oncology-related gene and cell therapy development.
• Genetic disorders- Genetic disorders hold a share of 25%, supported by rising therapeutic development targeting inherited and rare diseases.
• Infectious diseases- Infectious diseases account for a notable share of 15%, driven by continued investment in vaccine and antiviral therapeutic development.

Top Companies in the Middle East Viral Vectors and Plasmid DNA Manufacturing Market

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent Inc.
• Wuxi Biologics
• Takara Bio Inc.
• Waisman Biomanufacturing
• Genezen laboratories
• Batavia Biosciences
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• Audentes Therapeutics
• BioMarin Pharmaceutical
• RegenxBio, Inc.

Segments Covered in the Report

By Vector Type

• Adeno-associated virus (AAV)
• Lentivirus
• Adenovirus
• Retrovirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others